Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Aarti Drugs Ltd

AARTIDRUGS:NSI

Aarti Drugs Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)487.80
  • Today's Change3.65 / 0.75%
  • Shares traded22.44k
  • 1 Year change+6.22%
  • Beta1.0489
Data delayed at least 15 minutes, as of Nov 01 2024 13:49 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aarti Drugs Limited is an India-based company, which is engaged in manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals includes benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.

  • Revenue in INR (TTM)23.80bn
  • Net income in INR1.52bn
  • Incorporated1984
  • Employees1.06k
  • Location
    Aarti Drugs LtdMahendra Industrial Estate,Ground Floor, Road No 29, Plot No 109-D,MUMBAI 400022IndiaIND
  • Phone+91 2 224019025
  • Fax+91 2 224073462
  • Websitehttps://www.aartidrugs.co.in/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Indoco Remedies Ltd17.73bn320.40m28.60bn5.93k93.032.6320.981.613.343.34175.26118.230.81941.524.512,989,727.001.366.881.999.8568.3465.591.666.930.81421.710.433914.028.9113.41-30.78--34.5437.97
Dishman Carbogen Amcis Ltd24.16bn-2.48bn30.54bn1.13k----176.821.26-15.81-15.81154.06--------21,344,260.00---0.3986---0.488879.3073.83-10.27-1.54---0.7216----8.414.91-414.93---0.3175--
RPG Life Sciences Limited6.00bn923.20m41.48bn1.27k44.93--37.556.9255.8255.82362.60--------4,721,969.00--16.07--21.7768.4262.9915.3911.99--220.43--29.2713.5012.0129.6051.9828.6046.14
Solara Active Pharma Sciences Ltd12.22bn-5.36bn42.96bn2.16k--2.57--3.52-137.13-137.13320.29301.630.47311.772.695,667,023.00-20.76-2.44-36.40-3.8438.7041.16-43.89-4.490.448-1.300.4355---10.73-1.45-2,458.12---4.81--
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn43.37bn1.23k--137.18----------12.72------------------------0.8228--0.2681--43.84--77.37------
Morepen Laboratories Ltd17.45bn1.18bn43.77bn1.62k34.57--29.252.512.312.3134.26--------10,749,300.00--7.90--13.3437.8633.346.775.49--33.34--0.0019.2517.08148.6327.2247.03--
Gufic BioSciences Ltd8.14bn863.69m43.97bn1.45k50.41--42.505.408.708.7081.95--------5,624,707.00--11.46--19.2152.3945.7910.6010.46--8.09--1.3116.8018.128.0731.4653.8314.87
Aarti Drugs Ltd23.80bn1.52bn44.19bn1.06k29.133.4621.491.8616.6216.62259.74139.960.99543.163.4322,364,630.006.379.739.6215.7834.6022.236.408.251.016.830.3159---6.9010.133.0713.8224.96--
Innova Captab Ltd11.42bn1.06bn44.50bn--32.82--35.813.9023.6923.69236.62------------10.82--18.3833.3825.189.308.04--8.89----16.7224.9038.8436.55104.14--
SeQuent Scientific Ltd14.27bn54.87m45.44bn1.20k853.41--58.503.190.21370.213757.18--------11,939,190.00--1.09--1.7645.3841.970.99021.18--0.9009--35.06-3.605.6870.40--6.96--
Hikal Ltd18.03bn677.82m46.93bn2.06k69.28--24.772.605.495.49145.97--------8,749,879.00--5.07--7.5153.0646.783.765.86--2.45--12.19-11.792.34-11.20-7.559.720.00
Supriya Lifescience Ltd6.25bn1.58bn50.18bn448.0031.915.5428.718.0319.5419.5477.55112.560.67372.016.5613,950,510.0016.9819.0818.3824.0466.8157.1225.2024.714.05111.460.0062.8823.7415.4732.5624.7583.79--
Aarti Pharmalabs Ltd19.68bn2.28bn57.96bn1.63k25.413.1218.882.9525.1625.16217.12204.880.77331.624.5912,095,750.008.96--11.86--45.56--11.59--0.961117.120.1723---4.76--12.10------
Unichem Laboratories Ltd17.28bn-605.50m58.55bn3.19k----112.073.39-8.59-8.59245.15--------5,410,587.00---1.67---2.0362.0056.18-3.50-3.99--0.1401----26.947.6465.15---35.00--
Data as of Nov 01 2024. Currency figures normalised to Aarti Drugs Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

7.52%Per cent of shares held by top holders
HolderShares% Held
DSP Asset Managers Pvt. Ltd.as of 30 Sep 20245.41m5.88%
Dimensional Fund Advisors LPas of 03 Oct 2024627.94k0.68%
Mellon Investments Corp.as of 03 Oct 2024265.28k0.29%
ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 2024251.79k0.27%
BlackRock Advisors (UK) Ltd.as of 03 Oct 2024114.69k0.13%
BlackRock Fund Advisorsas of 03 Oct 2024104.10k0.11%
SSgA Funds Management, Inc.as of 03 Oct 202452.78k0.06%
TIAA-CREF Investment Management LLCas of 31 Aug 202433.65k0.04%
State Street Global Advisors Ltd.as of 02 Oct 202432.43k0.04%
American Century Investment Management, Inc.as of 03 Oct 202425.74k0.03%
More ▼
Data from 30 Jun 2024 - 24 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.